Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERCEPTION
2023-508155-40-00Phase 2Authorised
- Sponsor
- NOGGO
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by NOGGO. Primary endpoint: 12-month progression-free survival rate. Planned start Feb 2024; status: authorised.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-508155-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508155-40-00.